Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMCR NASDAQ:RGNX NASDAQ:SPRY NASDAQ:TARS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMCRImmunocore$34.92-1.5%$32.62$23.15▼$41.54$1.75B0.77343,934 shs14,998 shsRGNXREGENXBIO$9.02-0.5%$8.94$5.03▼$15.36$452.24M1.061.04 million shs23,108 shsSPRYARS Pharmaceuticals$18.02+0.2%$15.13$8.91▼$18.90$1.77B0.91.54 million shs57,641 shsTARSTarsus Pharmaceuticals$40.17-2.4%$42.53$20.08▼$57.28$1.69B0.8683,620 shs43,267 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMCRImmunocore+2.52%+7.39%-1.34%+33.32%-6.78%RGNXREGENXBIO-1.20%+3.78%-7.65%+53.82%-15.64%SPRYARS Pharmaceuticals+0.45%+9.07%+22.40%+27.97%+71.89%TARSTarsus Pharmaceuticals-0.31%+0.19%-0.02%-11.35%+45.96%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIMCRImmunocore1.2088 of 5 stars3.30.00.00.00.62.50.0RGNXREGENXBIO4.4137 of 5 stars3.43.00.04.61.43.30.6SPRYARS Pharmaceuticals3.1179 of 5 stars3.61.00.00.02.64.20.6TARSTarsus Pharmaceuticals2.1881 of 5 stars3.50.00.00.03.21.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMCRImmunocore 2.55Moderate Buy$58.8968.62% UpsideRGNXREGENXBIO 2.83Moderate Buy$31.63250.80% UpsideSPRYARS Pharmaceuticals 3.17Buy$31.0072.05% UpsideTARSTarsus Pharmaceuticals 3.00Buy$66.6765.96% UpsideCurrent Analyst Ratings BreakdownLatest RGNX, SPRY, TARS, and IMCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2025RGNXREGENXBIOChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$52.006/2/2025IMCRImmunocoreHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$100.006/2/2025TARSTarsus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$75.005/27/2025IMCRImmunocoreDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$65.005/27/2025TARSTarsus PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$72.005/8/2025IMCRImmunocoreOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$85.00 ➝ $86.005/5/2025TARSTarsus PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$46.00 ➝ $51.005/2/2025TARSTarsus PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$78.00 ➝ $84.004/17/2025RGNXREGENXBIOThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$14.00 ➝ $12.004/14/2025IMCRImmunocoreJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$54.00 ➝ $50.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMCRImmunocore$310.20M5.66N/AN/A$7.20 per share4.85RGNXREGENXBIO$83.33M5.43N/AN/A$5.24 per share1.72SPRYARS Pharmaceuticals$97.12M18.22$0.01 per share2,113.77$2.64 per share6.83TARSTarsus Pharmaceuticals$182.95M9.22N/AN/A$5.87 per share6.84Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMCRImmunocore-$51.09M-$0.43N/AN/AN/A-6.48%-5.86%-2.09%8/6/2025 (Estimated)RGNXREGENXBIO-$227.10M-$3.11N/AN/AN/A-100.62%-53.29%-30.84%8/7/2025 (Estimated)SPRYARS Pharmaceuticals$8M-$0.16N/AN/AN/A-16.11%-6.94%-5.60%8/5/2025 (Estimated)TARSTarsus Pharmaceuticals-$115.55M-$2.73N/AN/AN/A-44.91%-39.72%-25.74%8/6/2025 (Estimated)Latest RGNX, SPRY, TARS, and IMCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025RGNXREGENXBIO-$1.13N/AN/AN/AN/AN/A8/6/2025Q2 2025TARSTarsus Pharmaceuticals-$0.41N/AN/AN/A$95.81 millionN/A8/5/2025Q2 2025SPRYARS Pharmaceuticals-$0.42N/AN/AN/A$12.92 millionN/A5/14/2025Q1 2025SPRYARS Pharmaceuticals-$0.35-$0.35N/A-$0.35$7.48 million$7.97 million5/12/2025Q1 2025RGNXREGENXBIO$0.41$0.12-$0.29$0.12$105.35 million$89.01 million5/7/2025Q1 2025IMCRImmunocore-$0.35$0.10+$0.45$0.10$108.82 million$125.13 million5/1/2025Q1 2025TARSTarsus Pharmaceuticals-$0.69-$0.64+$0.05-$0.64$72.50 million$78.34 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMCRImmunocoreN/AN/AN/AN/AN/ARGNXREGENXBION/AN/AN/AN/AN/ASPRYARS PharmaceuticalsN/AN/AN/AN/AN/ATARSTarsus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMCRImmunocore1.036.366.31RGNXREGENXBION/A2.932.93SPRYARS Pharmaceuticals0.3011.0010.74TARSTarsus Pharmaceuticals0.215.575.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMCRImmunocore84.50%RGNXREGENXBIO88.08%SPRYARS Pharmaceuticals68.16%TARSTarsus Pharmaceuticals90.01%Insider OwnershipCompanyInsider OwnershipIMCRImmunocore10.40%RGNXREGENXBIO12.79%SPRYARS Pharmaceuticals33.50%TARSTarsus Pharmaceuticals8.97%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMCRImmunocore32050.23 million45.01 millionOptionableRGNXREGENXBIO37050.16 million43.75 millionOptionableSPRYARS Pharmaceuticals9098.21 million65.31 millionOptionableTARSTarsus Pharmaceuticals5042.01 million38.25 millionOptionableRGNX, SPRY, TARS, and IMCR HeadlinesRecent News About These CompaniesAllspring Global Investments Holdings LLC Sells 12,401 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)July 5, 2025 | marketbeat.comTarsus Pharmaceuticals Inc Ordinary Shares - MorningstarJuly 2, 2025 | morningstar.comMTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by Lisanti Capital Growth LLCJune 29, 2025 | marketbeat.comTarsus Pharmaceuticals Becomes Oversold (TARS)June 19, 2025 | nasdaq.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Bought by GAMMA Investing LLCJune 19, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Recommendation of "Buy" by BrokeragesJune 17, 2025 | marketbeat.comTarsus Pharmaceuticals CCO sells $765,800 in stockJune 13, 2025 | investing.comTarsus Pharmaceuticals CCO sells $765,800 in stockJune 13, 2025 | investing.comAssenagon Asset Management S.A. Decreases Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)June 12, 2025 | marketbeat.comStocks Showing Improving Market Leadership: Tarsus Pharmaceuticals Earns 87 RS RatingJune 6, 2025 | msn.comTarsus Pharmaceuticals assumed with an Outperform at OppenheimerJune 2, 2025 | msn.comTarsus to Participate in Upcoming Investor ConferencesMay 29, 2025 | globenewswire.comTarsus Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)May 27, 2025 | benzinga.comTarsus Pharmaceuticals at H.C. Wainwright: Expanding Horizons with XdemvyMay 21, 2025 | investing.comTarsus Pharmaceuticals (TARS) Loses -15.59% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerMay 14, 2025 | zacks.comTarsus Pharmaceuticals: The "Get Big Fast" Approach Could Pay OffMay 12, 2025 | seekingalpha.comTarsus to Participate in Upcoming Investor ConferencesMay 8, 2025 | globenewswire.com6 Analysts Assess Tarsus Pharmaceuticals: What You Need To KnowMay 5, 2025 | benzinga.comTarsus Pharmaceuticals, Inc. (TARS): Among the Best Breakout Stocks to Buy According to AnalystsMay 5, 2025 | insidermonkey.comUncovering Potential: Supernus Pharmaceuticals's Earnings PreviewMay 5, 2025 | benzinga.comElanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt PaydownMay 5, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRGNX, SPRY, TARS, and IMCR Company DescriptionsImmunocore NASDAQ:IMCR$34.92 -0.53 (-1.49%) As of 10:31 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.REGENXBIO NASDAQ:RGNX$9.02 -0.05 (-0.50%) As of 10:31 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.ARS Pharmaceuticals NASDAQ:SPRY$18.02 +0.04 (+0.21%) As of 10:31 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.Tarsus Pharmaceuticals NASDAQ:TARS$40.17 -0.99 (-2.41%) As of 10:31 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
